(-)-Lobeline

337.45528

337.46

202-012-3

DTXSID3023219

40.54000

3.61

1.1±0.1 g/cm3

130.5 °C

485.6±15.0 °C at 760 mmHg

247.5±20.4 °C

1.563

Subcutaneous-rat LDL0: 80 mg/kg; peritoneal-mouse LD50: 43.5 mg/kg

Lobelia leaves contain lobeline, and cannot be used as tea; thermal decomposition decomposes toxic nitrogen oxide fumes

D15 -43° (alc)

III

6.1(b)

1544

23/24/25

36/37/39-45

T

The warehouse is low-temperature, ventilated and dry; stored separately from food materials

|Danger|H301+H311+H331 (80.41%): Toxic if swallowed, in contact with skin or if inhaled [Danger Acute toxicity, oral; acute toxicity, dermal; acute toxicity, inhalation]|P261, P264, P270, P271, P280, P301+P310, P302+P352, P304+P340, P311, P312, P321, P322, P330, P361, P363, P403+P233, P405, and P501|Aggregated GHS information provided by 194 companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

highly toxic

Drugs that bind to and activate nicotinic cholinergic receptors (RECEPTORS, NICOTINIC). Nicotinic agonists act at postganglionic nicotinic receptors, at neuroeffector junctions in the peripheral nervous system, and at nicotinic receptors in the central nervous system. Agents that function as neuromuscular depolarizing blocking agents are included here because they activate nicotinic receptors, although they are used clinically to block nicotinic transmission. (See all compounds classified as Nicotinic Agonists.)|Agents that mimic neural transmission by stimulation of the nicotinic receptors on postganglionic autonomic neurons. Drugs that indirectly augment ganglionic transmission by increasing the release or slowing the breakdown of acetylcholine or by non-nicotinic effects on postganglionic neurons are not included here nor are the nonspecific cholinergic agonists. (See all compounds classified as Ganglionic Stimulants.)|Drugs used for their effects on the respiratory system. (See all compounds classified as Respiratory System Agents.)

Lobeline